EP1180937A1 - Souches de bacteriophages utiles pour sauver des patients infectes par enterococcus faecium resistant a la vancomycine - Google Patents
Souches de bacteriophages utiles pour sauver des patients infectes par enterococcus faecium resistant a la vancomycineInfo
- Publication number
- EP1180937A1 EP1180937A1 EP00931911A EP00931911A EP1180937A1 EP 1180937 A1 EP1180937 A1 EP 1180937A1 EP 00931911 A EP00931911 A EP 00931911A EP 00931911 A EP00931911 A EP 00931911A EP 1180937 A1 EP1180937 A1 EP 1180937A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- phage
- enterococcus faecium
- vancomycin
- enb6
- pta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10311—Siphoviridae
- C12N2795/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Definitions
- MDR Enterococcus faecium
- MDR multidrug resistant
- Synercid® recently entered the market as a treatment for vancomycin-resistant bacteria, including VREF.
- MDR bacteria are so efficient at resisting newer antibiotics (even those to which
- efflux pump can transport out many classes of drugs; and a mutation in the
- ribosomal subunit targeted by antibiotics can defeat several classes of drugs.
- Bacte ophage (phage) therapy offers one such alternative.
- phage strains for example ENB6
- phages tend to be rapidly cleared from the systemic circulation by the filtering action
- the technique also selects for those mutants that retain their ability to lyse the target
- phage stains that attack VREF hosts have
- Phage strains were grown by standard techniques known in the art,
- the ENB6 genome contains at least 120 kb of DNA as determined by
- nucleotide sequence has been defined at 99% confidence, while 24.7 kb has been defined at a lower level of confidence. The remaining amount is presently
- ENB6 nucleotide sequences have been compared to all genes and
- Figure 2 is an electron microscopic picture of phage ENB6.
- the routes of administration include but are not limited to: oral, aerosol or
- intrathecal intraperitoneal, intrathecal, vaginal, rectal, topical, lumbar puncture, intrathecal,
- the free phage could be in lyophilized form and be
- administration is contemplated to be in the range of about 10 3 to about 10 13
- the phage are Table 2. Proteins screened by PCR amplification of ENB6 DNA.
- the present invention will be particularly useful in treating critically ill
- ENB6 ATCC # PTA-40
- ENB13 ATCC # PTA-39
- Figures 3 and 4 show the results of a dose-finding study.
- CRMEN44 is 1 x 10 9 CFU, when injected I. P. into one month-old balb/c
- PFU plaque forming units PFU
- the non-parametric rating scale for observable signs of illness is as follows:
- Phage administered as a control did not produce any detectable symptoms in the
- Phage ENB6 rescues animals from an otherwise-fatal dose of VREF, a bacterial
- Figures 5 and 6 show the results of delay in the treatment of a fulminant
- VREF are orders-of-magnitude lower than the concentrations achieved here, so it
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
la présente invention concerne l'utilisation de bactériophages spécifiques, appelés ENB6 et ENB13, qui tuent nombre d'isolats cliniques de Enterococcus faecium résistant à la vancomycine et de Enterococcus faecium sensible à la vancomycine. Le génome d'une des souches de ces bactériophages, ENB6 à été partiellement séquencé, et il apparaît qu'il ne contient pas de séquences nucléotidiques correspondant à des gènes à virulence bactérienne connus et à une cassette présentant une résistance à la vancomycine. Son efficacité qui a permis de sauver des souris de bactériémie dont l'issue aurait en d'autres circonstances été fatale, est présentée dans ce dossier.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13405599P | 1999-05-13 | 1999-05-13 | |
US134055P | 1999-05-13 | ||
PCT/US2000/006718 WO2000069269A1 (fr) | 1999-05-13 | 2000-05-12 | Souches de bacteriophages utiles pour sauver des patients infectes par enterococcus faecium resistant a la vancomycine |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1180937A1 true EP1180937A1 (fr) | 2002-02-27 |
EP1180937A4 EP1180937A4 (fr) | 2004-08-04 |
Family
ID=22461568
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00931911A Withdrawn EP1180937A4 (fr) | 1999-05-13 | 2000-05-12 | Souches de bacteriophages utiles pour sauver des patients infectes par enterococcus faecium resistant a la vancomycine |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1180937A4 (fr) |
JP (1) | JP2002543816A (fr) |
AU (1) | AU4971900A (fr) |
CA (1) | CA2373486A1 (fr) |
WO (1) | WO2000069269A1 (fr) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1250143A2 (fr) | 2000-01-11 | 2002-10-23 | Intralytix Inc. | Reduction de la colonisation bacterienne par administration de compositions bacteriophages |
US6759229B2 (en) | 2001-12-18 | 2004-07-06 | President & Fellows Of Harvard College | Toxin-phage bacteriocide antibiotic and uses thereof |
GB0209680D0 (en) * | 2002-04-27 | 2002-06-05 | Univ Strathclyde | Immobilisation and stabilisation of bacteriophage |
WO2004052274A2 (fr) | 2002-12-09 | 2004-06-24 | Phage Biopharm Llc | Production de compositions bacteriophages destinees a etre utilisees dans la therapie phagique |
DE10342071B4 (de) * | 2003-09-10 | 2006-01-19 | Fleischmann, Wilhelm, Dr.med. | Vorrichtung und Verfahren zur Applikation von Wïrkstoffen an eine Wundoberfläche |
US8178087B2 (en) | 2006-04-04 | 2012-05-15 | Centre National de la Recherche Scientifique —CNRS | Process of production of bacteriophage compositions and methods in phage therapy field |
KR100958139B1 (ko) * | 2008-03-31 | 2010-05-18 | 주식회사 인트론바이오테크놀로지 | 엔테로코쿠스 패칼리스 특이적 사멸능을 갖는 신규한박테리오파지 |
PL215522B1 (pl) | 2008-09-29 | 2013-12-31 | Inst Immunologii I Terapii Doswiadczalnej Pan | Nowe szczepy bakteriofagów do leczenia zakazen bakteryjnych, zwlaszcza szczepami bakterii lekoopornych rodzaju Enterococcus |
KR100988771B1 (ko) * | 2008-09-29 | 2010-10-20 | 주식회사 인트론바이오테크놀로지 | 엔테로코쿠스 및 스트렙토코쿠스 특이적 사멸능을 갖는 신규한 리신 단백질 |
RU2580248C9 (ru) * | 2009-02-06 | 2018-01-17 | Текнофахе, Инвестигасао Э Десенвольвименто Эм Биотекнолохия, Са | Бактериофаг, обладащий активностью против pseudomonas aeruginosa, белки бактериофага и способы их применения |
WO2017177196A1 (fr) | 2016-04-08 | 2017-10-12 | The Trustees Of Princeton University | Nouvelles compositions antimicrobiennes et méthodes d'utilisation |
KR101957266B1 (ko) * | 2017-02-22 | 2019-03-13 | 주식회사 인트론바이오테크놀로지 | 엔테로코쿠스 패슘에 대하여 용균력을 가지는 신규한 항균단백질 efal-2 |
KR101822812B1 (ko) * | 2017-02-22 | 2018-01-29 | 주식회사 인트론바이오테크놀로지 | 신규한 엔테로코쿠스 패슘 박테리오파지 Ent-FAP-4 및 이의 엔테로코쿠스 패슘 증식 억제 용도 |
GB201712733D0 (en) | 2017-08-08 | 2017-09-20 | Snipr Tech Ltd | Methods & cells |
KR102203679B1 (ko) * | 2018-12-26 | 2021-01-15 | 주식회사 옵티팜 | 신규한 엔테로코커스 패시움 균 특이 박테리오파지 ef44 및 이를 포함하는 항균 조성물 |
GB201901099D0 (en) | 2019-01-27 | 2019-03-13 | Snipr Biome Aps | Methods, uses and compositions |
IL309276A (en) * | 2021-06-15 | 2024-02-01 | Ferring Bv | Bacteriophages against vancomycin-resistant enterococci |
WO2024003301A1 (fr) | 2022-06-29 | 2024-01-04 | Snipr Biome Aps | Ciblage de cellules d'e. coli |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5766892A (en) * | 1994-04-05 | 1998-06-16 | Exponential Biotherapies, Inc. | Antibacterial therapy with bacteriophage genotypically modified to delay inactivation by the host defense system together with an antibiotic |
-
2000
- 2000-05-12 JP JP2000617737A patent/JP2002543816A/ja active Pending
- 2000-05-12 EP EP00931911A patent/EP1180937A4/fr not_active Withdrawn
- 2000-05-12 CA CA002373486A patent/CA2373486A1/fr not_active Abandoned
- 2000-05-12 AU AU49719/00A patent/AU4971900A/en not_active Abandoned
- 2000-05-12 WO PCT/US2000/006718 patent/WO2000069269A1/fr not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5766892A (en) * | 1994-04-05 | 1998-06-16 | Exponential Biotherapies, Inc. | Antibacterial therapy with bacteriophage genotypically modified to delay inactivation by the host defense system together with an antibiotic |
Non-Patent Citations (2)
Title |
---|
ALISKY J ET AL: "BACTERIOPHAGE SHOW PROMISE AS ANTIMICROBIAL AGENTS" JOURNAL OF INFECTION, ACADEMIC PRESS, LONDON, GB, vol. 36, 1998, pages 5-15, XP000993238 ISSN: 0163-4453 * |
See also references of WO0069269A1 * |
Also Published As
Publication number | Publication date |
---|---|
JP2002543816A (ja) | 2002-12-24 |
AU4971900A (en) | 2000-12-05 |
WO2000069269A1 (fr) | 2000-11-23 |
CA2373486A1 (fr) | 2000-11-23 |
WO2000069269A9 (fr) | 2002-02-21 |
EP1180937A4 (fr) | 2004-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000069269A1 (fr) | Souches de bacteriophages utiles pour sauver des patients infectes par enterococcus faecium resistant a la vancomycine | |
Nishikawa et al. | T-even-related bacteriophages as candidates for treatment of Escherichia coli urinary tract infections | |
US5811093A (en) | Bacteriophage genotypically modified to delay inactivations by the host defense system | |
US11492378B2 (en) | Antibacterial protein EFAL-2 having bacteriolytic ability with respect to Enterococcus faecium | |
JP7449967B2 (ja) | 療法バクテリオファージ組成物 | |
CN112218659A (zh) | 用于治疗葡萄球菌感染的治疗性噬菌体组合物 | |
US20010043924A1 (en) | Antibacterial therapy with bacteriophage physico-chemically altered to delay inactivation by the host defense system | |
AU2004200450B2 (en) | Strains of bacteriophage useful for rescuing patients infected with vancomycin-resistant enterococcus faecium | |
WO2004020635A1 (fr) | Bacteriophages et remedes pour une infection bacterienne | |
CN115038799A (zh) | 治疗细菌感染的方法 | |
EP3442551B1 (fr) | Souche de bactériophage capable de produire une infection lytique dans le clone escherichia coli st131-o25b:h4 | |
WO2019191508A1 (fr) | Biomarqueur et cible de traitement pour l'hépatite alcoolique | |
US20240189373A1 (en) | Bacteriophage compositions for treating staphylococcus infection | |
EP3440200B1 (fr) | Bactériophage modifié | |
CN115725607A (zh) | 一种鼻疽诺卡菌的致病靶基因及其应用 | |
WO2023288334A1 (fr) | Procédé de traitement d'agents pathogènes eskape résistants aux médicaments à l'aide de bactériophages thérapeutiques | |
KR20230159558A (ko) | 장독소원성 박테로이데스 프라길리스의 증식을 억제하기 위한 조성물 및 방법 | |
Sahni | Review on Phage Therapy | |
Godány et al. | Phage therapy: Alternative approach to antibiotics | |
Lin et al. | Isolation of a bacteriophage and its depolymerase specific for K1 capsule of Klebsiella |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20011212 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20040623 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20051201 |